Single User License
INR 169825
Site License
INR 339650
Corporate User License
INR 509475

Service Tax Additional

select a format
Price

Single User License
USD 2500
Site License
USD 5000
Corporate User License
USD 7500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Melanoma-Pipeline Review, H1 2015

Melanoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Melanoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Melanoma-Pipeline Review, H1 2015', provides an overview of the Melanoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Melanoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Melanoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Melanoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Melanoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Melanoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Melanoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Melanoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Melanoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 11

Melanoma Overview 12

Therapeutics Development 13

Melanoma-Therapeutics under Development by Companies 15

Melanoma-Therapeutics under Investigation by Universities/Institutes 34

Melanoma-Pipeline Products Glance 40

Melanoma-Products under Development by Companies 44

Melanoma-Products under Investigation by Universities/Institutes 70

Melanoma-Companies Involved in Therapeutics Development 76

Melanoma-Therapeutics Assessment 281

Drug Profiles 324

Melanoma-Recent Pipeline Updates 994

Melanoma-Dormant Projects 1287

Melanoma-Discontinued Products 1318

Melanoma-Product Development Milestones 1322

Appendix 1331

List of Tables

Number of Products under Development for Melanoma, H1 2015 60

Number of Products under Development for Melanoma-Comparative Analysis, H1 2015 61

Number of Products under Development by Companies, H1 2015 63

Number of Products under Development by Companies, H1 2015 (Contd..1) 64

Number of Products under Development by Companies, H1 2015 (Contd..2) 65

Number of Products under Development by Companies, H1 2015 (Contd..3) 66

Number of Products under Development by Companies, H1 2015 (Contd..4) 67

Number of Products under Development by Companies, H1 2015 (Contd..5) 68

Number of Products under Development by Companies, H1 2015 (Contd..6) 69

Number of Products under Development by Companies, H1 2015 (Contd..7) 70

Number of Products under Development by Companies, H1 2015 (Contd..8) 71

Number of Products under Development by Companies, H1 2015 (Contd..9) 72

Number of Products under Development by Companies, H1 2015 (Contd..10) 73

Number of Products under Development by Companies, H1 2015 (Contd..11) 74

Number of Products under Development by Companies, H1 2015 (Contd..12) 75

Number of Products under Development by Companies, H1 2015 (Contd..13) 76

Number of Products under Development by Companies, H1 2015 (Contd..14) 77

Number of Products under Development by Companies, H1 2015 (Contd..15) 78

Number of Products under Development by Companies, H1 2015 (Contd..16) 79

Number of Products under Development by Companies, H1 2015 (Contd..17) 80

Number of Products under Investigation by Universities/Institutes, H1 2015 82

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 83

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 84

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 85

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 86

Comparative Analysis by Late Stage Development, H1 2015 87

Comparative Analysis by Clinical Stage Development, H1 2015 88

Comparative Analysis by Early Stage Development, H1 2015 89

Comparative Analysis by Unknown Stage Development, H1 2015 90

Products under Development by Companies, H1 2015 91

Products under Development by Companies, H1 2015 (Contd..1) 92

Products under Development by Companies, H1 2015 (Contd..2) 93

Products under Development by Companies, H1 2015 (Contd..3) 94

Products under Development by Companies, H1 2015 (Contd..4) 95

Products under Development by Companies, H1 2015 (Contd..5) 96

Products under Development by Companies, H1 2015 (Contd..6) 97

Products under Development by Companies, H1 2015 (Contd..7) 98

Products under Development by Companies, H1 2015 (Contd..8) 99

Products under Development by Companies, H1 2015 (Contd..9) 100

Products under Development by Companies, H1 2015 (Contd..10) 101

Products under Development by Companies, H1 2015 (Contd..11) 102

Products under Development by Companies, H1 2015 (Contd..12) 103

Products under Development by Companies, H1 2015 (Contd..13) 104

Products under Development by Companies, H1 2015 (Contd..14) 105

Products under Development by Companies, H1 2015 (Contd..15) 106

Products under Development by Companies, H1 2015 (Contd..16) 107

Products under Development by Companies, H1 2015 (Contd..17) 108

Products under Development by Companies, H1 2015 (Contd..18) 109

Products under Development by Companies, H1 2015 (Contd..19) 110

Products under Development by Companies, H1 2015 (Contd..20) 111

Products under Development by Companies, H1 2015 (Contd..21) 112

Products under Development by Companies, H1 2015 (Contd..22) 113

Products under Development by Companies, H1 2015 (Contd..23) 114

Products under Development by Companies, H1 2015 (Contd..24) 115

Products under Development by Companies, H1 2015 (Contd..25) 116

Products under Investigation by Universities/Institutes, H1 2015 117

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 118

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 119

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 120

Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 121

Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 122

Melanoma-Pipeline by 4SC AG, H1 2015 123

Melanoma-Pipeline by AB Science, H1 2015 124

Melanoma-Pipeline by AbbVie Inc., H1 2015 125

Melanoma-Pipeline by Adamis Pharmaceuticals Corporation, H1 2015 126

Melanoma-Pipeline by Adaptimmune Limited, H1 2015 127

Melanoma-Pipeline by Aduro BioTech, Inc., H1 2015 128

Melanoma-Pipeline by Advaxis, Inc., H1 2015 129

Melanoma-Pipeline by Aeterna Zentaris Inc., H1 2015 130

Melanoma-Pipeline by Affichem, H1 2015 131

Melanoma-Pipeline by Agalimmune Ltd, H1 2015 132

Melanoma-Pipeline by Agenus, Inc., H1 2015 133

Melanoma-Pipeline by AGV Discovery, SAS, H1 2015 134

Melanoma-Pipeline by AIMM Therapeutics B.V., H1 2015 135

Melanoma-Pipeline by Alethia Biotherapeutics Inc., H1 2015 136

Melanoma-Pipeline by Altor BioScience Corporation, H1 2015 137

Melanoma-Pipeline by Amgen Inc., H1 2015 138

Melanoma-Pipeline by Amorfix Life Sciences Ltd., H1 2015 139

Melanoma-Pipeline by Anavex Life Sciences Corp., H1 2015 140

Melanoma-Pipeline by Antigen Express, Inc., H1 2015 141

Melanoma-Pipeline by APEIRON Biologics AG, H1 2015 142

Melanoma-Pipeline by Aphios Corporation, H1 2015 143

Melanoma-Pipeline by APO-T B.V., H1 2015 144

Melanoma-Pipeline by Aposense Ltd., H1 2015 145

Melanoma-Pipeline by Applied Immune Technologies Ltd, H1 2015 146

Melanoma-Pipeline by Aptose Biosciences Inc., H1 2015 147

Melanoma-Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015 148

Melanoma-Pipeline by Array BioPharma Inc., H1 2015 149

Melanoma-Pipeline by Arrowhead Research Corporation, H1 2015 150

Melanoma-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 151

Melanoma-Pipeline by AstraZeneca Plc, H1 2015 152

Melanoma-Pipeline by Aura Biosciences, Inc., H1 2015 153

Melanoma-Pipeline by Aurigene Discovery Technologies Limited, H1 2015 154

Melanoma-Pipeline by AVAX Technologies, Inc., H1 2015 155

Melanoma-Pipeline by Axelar AB, H1 2015 156

Melanoma-Pipeline by Azaya Therapeutics Incorporated, H1 2015 157

Melanoma-Pipeline by Basilea Pharmaceutica AG, H1 2015 158

Melanoma-Pipeline by Bayer AG, H1 2015 159

Melanoma-Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 160

Melanoma-Pipeline by Bio-Cancer Treatment International Limited, H1 2015 161

Melanoma-Pipeline by Biogenomics Limited, H1 2015 162

Melanoma-Pipeline by BioLineRx, Ltd., H1 2015 163

Melanoma-Pipeline by Bioncotech Therapeutics S.L., H1 2015 164

Melanoma-Pipeline by Bionomics Limited, H1 2015 165

Melanoma-Pipeline by BioNTech AG, H1 2015 166

Melanoma-Pipeline by Bioo Therapeutics, H1 2015 167

Melanoma-Pipeline by Biovista Inc., H1 2015 168

Melanoma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 169

Melanoma-Pipeline by Boston Biomedical, Inc., H1 2015 170

Melanoma-Pipeline by Bristol-Myers Squibb Company, H1 2015 171

Melanoma-Pipeline by Caladrius Biosciences, Inc. , H1 2015 172

Melanoma-Pipeline by Cantargia AB, H1 2015 173

Melanoma-Pipeline by cCAM Biotherapeutics Ltd., H1 2015 174

Melanoma-Pipeline by CCRP Therapeutics GmbH, H1 2015 175

Melanoma-Pipeline by Celgene Corporation, H1 2015 176

Melanoma-Pipeline by Celldex Therapeutics, Inc., H1 2015 177

Melanoma-Pipeline by Celyad, H1 2015 178

Melanoma-Pipeline by Champions Oncology, Inc., H1 2015 179

Melanoma-Pipeline by Cipher Pharmaceuticals Inc., H1 2015 180

Melanoma-Pipeline by Conkwest, Inc., H1 2015 181

Melanoma-Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2015 182

Melanoma-Pipeline by CSL Limited, H1 2015 183

Melanoma-Pipeline by CureFAKtor Pharmaceuticals, LLC, H1 2015 184

Melanoma-Pipeline by CureTech Ltd., H1 2015 185

Melanoma-Pipeline by Cytune Pharma SAS, H1 2015 186

Melanoma-Pipeline by CZ BioMed Corp, H1 2015 187

Melanoma-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 188

Melanoma-Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 189

Melanoma-Pipeline by Delcath Systems, Inc., H1 2015 190

Melanoma-Pipeline by DermaXon, LLC, H1 2015 191

Melanoma-Pipeline by Dicerna Pharmaceuticals, Inc., H1 2015 192

Melanoma-Pipeline by Digna Biotech, S.L., H1 2015 193

Melanoma-Pipeline by DNA Therapeutics S.A., H1 2015 194

Melanoma-Pipeline by DormaTarg, Inc., H1 2015 195

Melanoma-Pipeline by EcoBiotics Limited, H1 2015 196

Melanoma-Pipeline by Egenix, Inc., H1 2015 197

Melanoma-Pipeline by Eisai Co., Ltd., H1 2015 198

Melanoma-Pipeline by Eli Lilly and Company, H1 2015 199

Melanoma-Pipeline by EntreChem, S.L., H1 2015 200

Melanoma-Pipeline by Erytech Pharma SA, H1 2015 201

Melanoma-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 202

Melanoma-Pipeline by FirstString Research, Inc., H1 2015 203

Melanoma-Pipeline by Formune S.L., H1 2015 204

Melanoma-Pipeline by Galapagos NV, H1 2015 205

Melanoma-Pipeline by Galectin Therapeutics, Inc., H1 2015 206

Melanoma-Pipeline by Galileo Research s.r.l., H1 2015 207

Melanoma-Pipeline by Genelux Corporation, H1 2015 208

Melanoma-Pipeline by Genticel S.A., H1 2015 209

Melanoma-Pipeline by Genzyme Corporation, H1 2015 210

Melanoma-Pipeline by GlaxoSmithKline Plc, H1 2015 211

Melanoma-Pipeline by Gradalis Inc., H1 2015 212

Melanoma-Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015 213

Melanoma-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 214

Melanoma-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 215

Melanoma-Pipeline by Hemispherx Biopharma, Inc., H1 2015 216

Melanoma-Pipeline by Histogen, Inc., H1 2015 217

Melanoma-Pipeline by Ignyta, Inc., H1 2015 218

Melanoma-Pipeline by Immodulon Therapeutics Ltd., H1 2015 219

Melanoma-Pipeline by Immune Design Corp., H1 2015 220

Melanoma-Pipeline by Immune Response BioPharma, Inc., H1 2015 221

Melanoma-Pipeline by ImmunGene, Inc., H1 2015 222

Melanoma-Pipeline by ImmunNovative Developments SL, H1 2015 223

Melanoma-Pipeline by Immunocore Limited, H1 2015 224

Melanoma-Pipeline by ImmunoFrontier, Inc., H1 2015 225

Melanoma-Pipeline by ImmunoGen, Inc., H1 2015 226

Melanoma-Pipeline by Immunomic Therapeutics, Inc., H1 2015 227

Melanoma-Pipeline by Immunophotonics Inc, H1 2015 228

Melanoma-Pipeline by ImmuRx, Inc., H1 2015 229

Melanoma-Pipeline by IMPACT Therapeutics, Inc., H1 2015 230

Melanoma-Pipeline by Imugene Limited, H1 2015 231

Melanoma-Pipeline by Incyte Corporation, H1 2015 232

Melanoma-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 233

Melanoma-Pipeline by InteRNA Technologies B.V., H1 2015 234

Melanoma-Pipeline by ISA Pharmaceuticals B.V., H1 2015 235

Melanoma-Pipeline by Kadmon Corporation, LLC, H1 2015 236

Melanoma-Pipeline by KAEL-GemVax Co., Ltd., H1 2015 237

Melanoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 238

Melanoma-Pipeline by Laboratoires Pierre Fabre SA, H1 2015 239

Melanoma-Pipeline by Lentigen Technology, Inc., H1 2015 240

Melanoma-Pipeline by Life Science Pharmaceuticals, Incorporated, H1 2015 241

Melanoma-Pipeline by Lindis Biotech GmbH, H1 2015 242

Melanoma-Pipeline by Lipotek Pty Ltd., H1 2015 243

Melanoma-Pipeline by Luitpold Pharmaceuticals, Inc., H1 2015 244

Melanoma-Pipeline by Lytix Biopharma AS, H1 2015 245

Melanoma-Pipeline by MacroGenics, Inc., H1 2015 246

Melanoma-Pipeline by Magnus Life Science, H1 2015 247

Melanoma-Pipeline by MediaPharma s.r.l., H1 2015 248

Melanoma-Pipeline by MedImmune, LLC, H1 2015 249

Melanoma-Pipeline by Merck & Co., Inc., H1 2015 250

Melanoma-Pipeline by Merck KGaA, H1 2015 251

Melanoma-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 252

Melanoma-Pipeline by Mologen AG, H1 2015 253

Melanoma-Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 254

Melanoma-Pipeline by Morphotek, Inc., H1 2015 255

List of Figures

Number of Products under Development for Melanoma, H1 2015 60

Number of Products under Development for Melanoma-Comparative Analysis, H1 2015 61

Number of Products under Development by Companies, H1 2015 62

Number of Products under Investigation by Universities/Institutes, H1 2015 81

Comparative Analysis by Late Stage Development, H1 2015 87

Comparative Analysis by Clinical Stage Development, H1 2015 88

Comparative Analysis by Early Stage Products, H1 2015 89

Assessment by Monotherapy Products, H1 2015 328

Assessment by Combination Products, H1 2015 329

Number of Products by Top 10 Targets, H1 2015 330

Number of Products by Stage and Top 10 Targets, H1 2015 330

Number of Products by Top 10 Mechanism of Actions, H1 2015 352

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 352

Number of Products by Top 10 Routes of Administration, H1 2015 367

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 367

Number of Products by Top 10 Molecule Types, H1 2015 369

Number of Products by Stage and Top 10 Molecule Types, H1 2015 369

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AB Science

AbbVie Inc.

Adamis Pharmaceuticals Corporation

Adaptimmune Limited

Aduro BioTech, Inc.

Advaxis, Inc.

Aeterna Zentaris Inc.

Affichem

Agalimmune Ltd

Agenus, Inc.

AGV Discovery, SAS

AIMM Therapeutics B.V.

Alethia Biotherapeutics Inc.

Altor BioScience Corporation

Amgen Inc.

Amorfix Life Sciences Ltd.

Anavex Life Sciences Corp.

Antigen Express, Inc.

APEIRON Biologics AG

Aphios Corporation

APO-T B.V.

Aposense Ltd.

Applied Immune Technologies Ltd

Aptose Biosciences Inc.

Arisaph Pharmaceuticals, Inc.

Array BioPharma Inc.

Arrowhead Research Corporation

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

Aura Biosciences, Inc.

Aurigene Discovery Technologies Limited

AVAX Technologies, Inc.

Axelar AB

Azaya Therapeutics Incorporated

Basilea Pharmaceutica AG

Bayer AG

Bellicum Pharmaceuticals, Inc.

Bio-Cancer Treatment International Limited

Biogenomics Limited

BioLineRx, Ltd.

Bioncotech Therapeutics S.L.

Bionomics Limited

BioNTech AG

Bioo Therapeutics

Biovista Inc.

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

Caladrius Biosciences, Inc.

Cantargia AB

cCAM Biotherapeutics Ltd.

CCRP Therapeutics GmbH

Celgene Corporation

Celldex Therapeutics, Inc.

Celyad

Champions Oncology, Inc.

Cipher Pharmaceuticals Inc.

Conkwest, Inc.

Cornerstone Pharmaceuticals, Inc.

CSL Limited

CureFAKtor Pharmaceuticals, LLC

CureTech Ltd.

Cytune Pharma SAS

CZ BioMed Corp

Daiichi Sankyo Company, Limited

Deciphera Pharmaceuticals, LLC

Delcath Systems, Inc.

DermaXon, LLC

Dicerna Pharmaceuticals, Inc.

Digna Biotech, S.L.

DNA Therapeutics S.A.

DormaTarg, Inc.

EcoBiotics Limited

Egenix, Inc.

Eisai Co., Ltd.

Eli Lilly and Company

EntreChem, S.L.

Erytech Pharma SA

F. Hoffmann-La Roche Ltd.

FirstString Research, Inc.

Formune S.L.

Galapagos NV

Galectin Therapeutics, Inc.

Galileo Research s.r.l.

Genelux Corporation

Genticel S.A.

Genzyme Corporation

GlaxoSmithKline Plc

Gradalis Inc.

Hadasit Medical Research Services & Development Ltd

HanAll Biopharma Co., Ltd.

Hanmi Pharmaceuticals, Co. Ltd.

Hemispherx Biopharma, Inc.

Histogen, Inc.

Ignyta, Inc.

Immodulon Therapeutics Ltd.

Immune Design Corp.

Immune Response BioPharma, Inc.

ImmunGene, Inc.

ImmunNovative Developments SL

Immunocore Limited

ImmunoFrontier, Inc.

ImmunoGen, Inc.

Immunomic Therapeutics, Inc.

Immunophotonics Inc

ImmuRx, Inc.

IMPACT Therapeutics, Inc.

Imugene Limited

Incyte Corporation

Inovio Pharmaceuticals, Inc.

InteRNA Technologies B.V.

ISA Pharmaceuticals B.V.

Kadmon Corporation, LLC

KAEL-GemVax Co., Ltd.

Karyopharm Therapeutics, Inc.

Laboratoires Pierre Fabre SA

Lentigen Technology, Inc.

Life Science Pharmaceuticals, Incorporated

Lindis Biotech GmbH

Lipotek Pty Ltd.

Luitpold Pharmaceuticals, Inc.

Lytix Biopharma AS

MacroGenics, Inc.

Magnus Life Science

MediaPharma s.r.l.

MedImmune, LLC

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals, Inc.

Mologen AG

Momenta Pharmaceuticals, Inc.

Morphotek, Inc.

MSM Protein Technologies, Inc.

Multimmune GmbH

Navigen Pharmaceuticals, Inc.

Nektar Therapeutics

Neumedicines Inc.

NewLink Genetics Corporation

Northwest Biotherapeutics, Inc.

Novartis AG

Novogen Limited

Omeros Corporation

Oncology Research International Limited

Oncolytics Biotech Inc.

OncoNOx ApS

OncoSec Medical Inc.

Oncovir, Inc.

Ono Pharmaceutical Co., Ltd.

Otsuka Holdings Co., Ltd.

Pacific Northwest Biotechnology, LLC

Panacela Labs, Inc.

Patrys Limited

PDS Biotechnology Corporation

PEP-Therapy SAS

PepTx, Inc.

Peregrine Pharmaceuticals, Inc.

Pfizer Inc.

Pharminox Limited

Pharmis Biofarmaceutica, Lda.

Philogen S.p.A.

PinCell srl

Pivotal BioSciences, Inc.

Plexxikon Inc.

Polaris Pharmaceuticals, Inc.

Polyphor Ltd.

Priaxon AG

Provectus Biopharmaceuticals, Inc.

Provenance Biopharmaceuticals Corp.

Qu Biologics Inc.

Reata Pharmaceuticals, Inc.

Recepta Biopharma S.A.

Recombio S.L

Rigontec GmbH

RXi Pharmaceuticals Corporation

Scancell Holdings Plc

SK Biopharmaceuticals Co., Ltd.

Spectrum Pharmaceuticals, Inc.

Summit Therapeutics Plc

Sutro Biopharma, Inc.

Syndax Pharmaceuticals, Inc.

Synta Pharmaceuticals Corp.

Taiga Biotechnologies, Inc.

Takara Bio Inc.

Takeda Pharmaceutical Company Limited

Targovax AS

TC BioPharm Limited

tella Inc

Teva Pharmaceutical Industries Limited

Theravectys S.A.

TheRyte Limited

Threshold Pharmaceuticals, Inc.

Treat U, S.A.

TVAX Biomedical, Inc.

TyrNovo Ltd.

Ultimovacs AS

Vaccibody AS

Vaxeal Holding SA

Viralytics Ltd.

ViraTherapeutics GmbH

Virttu Biologics Limited

Viventia Biotechnologies Inc.

Welichem Biotech Inc.

WntResearch AB

ZIOPHARM Oncology, Inc.

Melanoma Therapeutic Products under Development, Key Players in Melanoma Therapeutics, Melanoma Pipeline Overview, Melanoma Pipeline, Melanoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com